The announcement of the publication of research confirming the mechanism of action of Simufilam in Alzheimer's disease is a significant development for Cassava Sciences. This could potentially lead to a breakthrough in Alzheimer's treatment, which would significantly boost the company's reputation and potentially its stock price.